a nonsignificant trendP = 0.089
In stages III and IV cancers, low levels of Bif-1 expression were associated with a nonsignificant trend toward a poorer clinical outcome ( P = 0.089; Figure 2(b) , and P = 0.158; Figure 2(c) , resp.).
In stages III and IV cancers, low levels of Bif-1 expression were associated with a nonsignificant trend toward a poorer clinical outcome ( P = 0.089; Figure 2(b) , and P = 0.158; Figure 2(c) , resp.).